Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Eleven Biotherapeutics Inc. (NASDAQ: EBIO) shares declined 4.63 percent to close at $15.45 a share Monday. The stock traded between $14.79 and $16.78 on volume of 113,833 shares traded. Analysts at Citigroup have recently initiated coverage on the company with a “buy” rating and a price target of $30.00. Shares of Eleven Biotherapeutics have gained approximately 42.0 percent year-to-date.
Find out more about Eleven Biotherapeutics including full access to the free equity report at:
Idera Pharmaceuticals Inc. (NASDAQ: IDRA) shares declined 2.42 percent to close at $5.65 a share Monday. The stock traded between $5.57 and $5.90 on volume of 2.74 million shares traded. Analysts at Cowen have recently initiated coverage on the company with an “outperform” rating. Shares of Idera Pharmaceuticals have gained approximately 22.0 percent year-to-date.
Find out more about Idera Pharmaceuticals including full access to the free equity report at:
Kronos Worldwide, Inc. (NYSE: KRO) shares increased 1.90 percent to close at $15.57 a share Monday. The stock traded between $15.50 and $16.17 on volume of 452,871 shares traded. Analysts at Wells Fargo have recently upgraded the company’s rating to “market perform” from “underperform”. Shares of Kronos Worldwide have fallen approximately 18.0 percent year-to-date.
Find out more about Kronos Worldwide including full access to the free equity report at:
RPM International Inc. (NYSE: RPM) shares increased 0.93 percent to close at $42.25 a share Monday. The stock traded between $41.94 and $42.47 on volume of 751,755 shares traded. Analysts at Credit Suisse have recently upgraded the company’s rating to “outperform” from “neutral”. Shares of RPM International have gained approximately 2.0 percent year-to-date.
Find out more about RPM International including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing